Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.59 |
| ▸ | RAB9A | P51151 | 6/20 | 0.59 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.56 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.56 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.56 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | F10 | P00742 | 1/20 | 0.55 |
| ▸ | PLG | P00747 | 1/20 | 0.55 |
| ▸ | PLAU | P00749 | 1/20 | 0.55 |
| ▸ | PLAT | P00750 | 1/20 | 0.55 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.55 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4804024 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9ACSNK2A2CSNK2B | |
| SCHEMBL4804018 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9ACSNK2A2CSNK2B | |
| SCHEMBL7298450 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9ACSNK2A2CSNK2B | |
| SCHEMBL12914553 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACSNK2A2CSNK2B | |
| SCHEMBL7298453 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9ACSNK2A2CSNK2B | |
| SCHEMBL24524106 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9ACSNK2A2CSNK2B | |
| SCHEMBL14422342 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9ACSNK2A2CSNK2B | |
| SCHEMBL14000532 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9ACSNK2A2CSNK2B | |
| SCHEMBL21217197 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACSNK2A2CSNK2B | |
| SCHEMBL11974092 | 0.80 | PLCG2 (0.78) | SMN1; SMN2NPC1RAB9ACSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023098640-A1 | PREPARATION METHOD FOR DRUG INTERMEDIATE | 浙江华海药业股份有限公司 | 2023-06-08 | — | — | WO | disclosed |
| EP-1072948-B1 | Thermally processed image recording material | FUJIFILM CORP (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| EP-0990946-B1 | Heat-developable photosensitive material | FUJIFILM CORP (JP) | 2009-09-09 | — | — | EP | disclosed |
| EP-1069469-B1 | Thermally processed image forming material | FUJIFILM CORP (JP) | 2008-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | SMN1; SMN2 1407/4885NPC1 655/4885RAB9A 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.